With Gilead and AbbVie posting essentially perfect phase 2 data with their hepatitis-C treatments, the bar has been set very high for those looking to join the race. To that end, Achillion shares are under pressure today after releasing interim data for one of its NS5A inhibitors targeting the disease. As Brenton Flynn discusses in the following video, this severe reaction to such a small data set reflects the paradigm shift in investor expectations around hepatitis-C treatments.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 09/22/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.